Ultragenyx Pharmaceutical (RARE)
NASDAQ:RARE
Holding RARE?
Track your performance easily

Ultragenyx Pharmaceutical (RARE) Ownership - Who Owns Ultragenyx Pharmaceutical?

744 Followers

Ultragenyx Pharmaceutical (RARE) Ownership Overview

3.98%29.94%2.29%14.48%49.30%
2.29% Other Institutional Investors
14.48% ETFs
49.30% Public Companies and Individual Investors
The ownership structure of Ultragenyx Pharmaceutical (RARE) stock is a mix of institutional, retail, and individual investors. Approximately 46.72% of the company’s stock is owned by Institutional Investors, 3.98% is owned by Insiders, and 49.30% is owned by Public Companies and Individual Investors.
The ownership structure of {name} ({ticker}) stock is a mix of institutional, retail, and individual investors. {displayInstitutionalData, select, display {Approximately {institutionalPercentage} of the company’s stock is owned by Institutional Investors} other {}}{displayInsiderText, select, display {, {insidersPercentage} is owned by Insiders} other {}}{displayInvestorsText, select, display {, and {retailInvestorsPercentage} is owned by Public Companies and Individual Investors.} other {}}

Recent Insider Trading Activity

Date
Name
Activity
Value
Oct 11, 2024
xxxxxxxxxxxxx
$393853
Sep 05, 2024
Emil Kakkis
President & Ceo,director
xxxxxxxxxxxxx
$1117000
Aug 07, 2024
Emil Kakkis
President & Ceo,director
xxxxxxxxxxxxx
$1003400
Jul 03, 2024
xxxxxxxxxxxxx
$23932

Recent Hedge Fund Trading Activity

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
8,056,517Institution8.74%420,389,057
7,366,916Institution7.99%384,405,677
5,354,750Institution5.81%279,410,855
2,788,582Insider3.03%145,508,209
2,247,991Institution2.44%117,300,170
2,190,840Institution2.38%114,318,031
2,082,400Institution2.26%108,659,632
1,787,637Institution1.94%93,278,899
1,466,547Institution1.59%76,524,422
1,462,138Institution1.59%76,294,361

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
7,366,916Institution7.99%384,405,677
2,190,840Institution2.38%114,318,031
2,082,400Institution2.26%108,659,632
1,787,637Institution1.94%93,278,899
1,462,138Institution1.59%76,294,361
1,082,366Institution1.17%56,477,858
974,312Institution1.06%50,839,600
949,273Institution1.03%49,533,065
942,508Institution1.02%49,180,067
900,881Institution0.98%47,007,971

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
2,809,832Institution3.05%156,086,168
2,191,348Institution2.38%121,729,381
1,379,587Institution1.50%76,636,058
1,208,644Institution1.31%67,140,174
1,082,622Institution1.17%56,491,216
607,098Institution0.66%30,670,591
490,161Institution0.53%25,576,601
494,674Institution0.54%24,990,930
444,232Institution0.48%23,180,026
318,949Institution0.35%16,113,303

FAQ

Who Owns Ultragenyx Pharmaceutical (RARE)?
According to the latest TipRanks data, approximately 2.29% of the company's stock is held by institutional investors, 3.98% is held by insiders, and 49.30% is held by retail investors.
    What percentage of Ultragenyx Pharmaceutical (RARE) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 2.29% of Ultragenyx Pharmaceutical (RARE) stock is held by institutional investors.
      What percentage of Ultragenyx Pharmaceutical (RARE) stock is held by retail investors?
      According to the latest TipRanks data, approximately 49.30% of Ultragenyx Pharmaceutical (RARE) stock is held by retail investors.
        Who owns the most shares of Ultragenyx Pharmaceutical (RARE)?
        Vanguard owns the most shares of Ultragenyx Pharmaceutical (RARE).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis